Treatment

Otezla 10mg clinical trials

5 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis
This study is testing a new drug, TAK-279, for people with moderate to severe plaque psoriasis. We want to see if it's safe and effective compared to a known treatment (Otezla) and a dummy pill (placebo) to help clear up skin patches.
For: Moderate to Severe Plaque Psoriasis
Poland · Italy · Germany
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
This study is testing a new medicine, ESK-001, for people with moderate to severe plaque psoriasis. Researchers want to see if it's safe and helps clear up skin patches better than a dummy pill or an existing medicine (Otezla).
For: Moderate to Severe Plaque Psoriasis
Poland · Germany · Spain
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3B, Multi Center, Open-label Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis
This study looks at a medicine called apremilast (Otezla) for young people aged 6 to 17 with moderate to severe psoriasis. It's a long-term study to see how safe and effective the medicine is, and how it affects their growth and development.
For: Moderate to Severe Plaque Psoriasis
Spain · Czechia · Belgium
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine, ZASOCITINIB (also called TAK-279), for people with moderate to severe plaque psoriasis. It compares the new medicine to existing treatments like Otezla and a dummy pill (placebo) to see how well it works and if it's safe.
For: Moderate to Severe Plaque Psoriasis
Germany · Poland · Latvia
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1)
This study is testing a new medicine, ESK-001, for people with moderate to severe plaque psoriasis. It compares ESK-001 to a common treatment (Otezla) and a dummy pill (placebo) to see how well it works and if it's safe.
For: Moderate to Severe Plaque Psoriasis
Bulgaria · Belgium · Portugal

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)

A Phase 3B, Multi Center, Open-label Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1)